Trastuzumab duocarmazine
Trastuzumab duocarmazine is an antibody drug conjugate pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
961 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 163 | 387 | 135 | 12 | 46 | 670 |
| Neoplasms | D009369 | — | C80 | 35 | 31 | 4 | 1 | 8 | 73 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 15 | 38 | 11 | 1 | 5 | 61 |
| Male breast neoplasms | D018567 | — | — | 9 | 11 | 2 | 1 | — | 20 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 10 | 14 | 1 | — | 1 | 23 |
| Adenocarcinoma | D000230 | — | — | 3 | 17 | 2 | — | 2 | 20 |
| Colorectal neoplasms | D015179 | — | — | 7 | 15 | 1 | — | 1 | 20 |
| Esophageal neoplasms | D004938 | — | C15 | 7 | 10 | 2 | — | — | 16 |
| Triple negative breast neoplasms | D064726 | — | — | 7 | 10 | 1 | — | — | 15 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 6 | 11 | 1 | — | — | 15 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 8 | 1 | — | — | 11 |
| Inflammatory breast neoplasms | D058922 | — | — | 3 | 4 | 3 | — | — | 9 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 3 | 5 | 1 | — | — | 8 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 5 | 1 | — | — | 6 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 8 | 8 | — | — | — | 14 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 8 | 6 | — | — | — | 11 |
| Urinary bladder neoplasms | D001749 | — | C67 | 4 | 9 | — | — | — | 11 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 6 | 4 | — | — | 1 | 10 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 4 | 8 | — | — | 1 | 10 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 3 | — | — | 1 | 6 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 5 | — | — | — | 6 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 2 | 4 | — | — | — | 6 |
| Rectal neoplasms | D012004 | — | — | 1 | 5 | — | — | — | 6 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | 5 | — | — | — | 6 |
Show 43 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | — | — | — | — | 14 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Show 31 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Observation | D019370 | — | — | — | — | — | — | 1 | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Second primary neoplasms | D016609 | — | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trastuzumab duocarmazine |
| INN | trastuzumab duocarmazine |
| Description | Trastuzumab duocarmazine is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298178 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | XCR2BZ80N7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 471 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use